Mostrando 7 resultados de: 7
Filtros aplicados
Subtipo de publicación
Article(7)
Publisher
CJC Open(1)
Canadian Journal of Cardiology(1)
Circulation(1)
European Heart Journal - Cardiovascular Pharmacotherapy(1)
Journal of the American College of Cardiology(1)
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
ArticleAbstract: Background: The large number of patients worldwide infected with the SARS-CoV-2 virus has overwhelmePalabras claves:Autores:Ali Z., Anand S.S., Avezum A.J., Bangdiwala S.I., Belley-Cote E.P., Berwanger O., Bosch J.J., Choudhri S., Dans A.L., Eikelboom J.W., Farkouh M.E., Felix Camilo, Harper W.L., Hassany M., Heenan L., Jolly S.S., Kontsevaya A., Loeb M., Lopes R.D., Pais P., Palileo-Villanueva L.M., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Sharma S.K., Tarhuni W.M., Wasserman S., Whitlock R.P., Xavier D., Xu L., Yusuf S., Yusufali A.M.Fuentes:googlescopusBleeding and New Cancer Diagnosis in Patients With Atherosclerosis
ArticleAbstract: BACKGROUND: Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be thePalabras claves:aspirin, hemorrhage, neoplasms, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Connolly S.J., Cook-Bruns N., Eikelboom J.W., Felix Camilo, Fox K.A.A., Hart R.G., Maggioni A.P., Moayyedi P., O’Donnell M., Rydén L.E., Shestakovska O., Verhamme P.B., Widimsky P., Yusuf S., Zhu J.Fuentes:googlescopusMortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
ArticleAbstract: Background: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily comparedPalabras claves:aspirin, Coronary artery disease, Mortality , Peripheral artery disease, rivaroxabanAutores:Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Connolly S.J., Dagenais G.R., Eikelboom J.W., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Maggioni A.P., Muehlhofer E., Sharma M., Shestakovska O., Yusuf S.Fuentes:googlescopusLong-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
ArticleAbstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheralPalabras claves:aspirin, Coronary artery disease, Peripheral artery disease, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.Fuentes:scopusRationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
ArticleAbstract: Background Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alPalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Ha J.W., Hart R.G., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Lanius V., Leong D.P., Lewis B.S., Liang Y., Liu L., Lonn E.M., Maggioni A.P., Metsarinne K.P., Misselwitz F., Moayyedi P., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yuan F., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusRivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
ArticleAbstract: Background: Patients with peripheral artery disease have an increased risk of cardiovascular morbidiPalabras claves:Autores:Aboyans V., ABRANTES J.A., AHUAD GUERRERO R.A., ALBISU DI GENNERO J.P., Alings M., ALVAREZ M., Anand S.S., Avezum A.J., Bangdiwala S.I., Barbieri M., BARTOLACCI I.P., Bhatt D.L., BORDONAVA A.P., Bosch J.J., Branch K.R.H., CACCAVO A., CARDONA M., CARTASEGNA L.U.I.S., Chacón C., Chen E., Commerford P.J., Connolly S.J., COSTABEL J.P., CUADRADO J., Cuneo C.A., DEBONNAIRE P., DIaz R., DRAN R.D., DUJARDIN K.A.R.L., ECTOR B.A.V.O., Eikelboom J.W., ELEGEERT I.V.A.N., FERRE PACORA F.A., Fox K.A.A., GARCIA DURAN R.O., GARRIDO M., Gomez Vilamajo O., GONZALEZ COLASO P.D.C., GRINFELD D., GUZMAN L.U.I.S., Hart R.G., HASBANI E., HERNANDES M., HOFFER E., HOMINAL M.A., HRABAR A., IBANEZ SAGGIA L.M., INDIO DO BRASIL C., Ingaramo A., Kakkar A.K., Keltai K., Leong D.P., LEROY J.E.A.N., Lewis B.S., LITVAK BRUNO M.R., LUCIARDI H.L., LUQUEZ H.U.G.O., MACIN S.M., MACKINNON I.J., MAFFEI L.E., Maggioni A.P., Maia L.N., MAJUL C.R., MANENTI E., Misselwitz F., Montaña O., NANI S., Novaretto L., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, PELAGAGGE M.J., Pogosova N., Precoma D.B., Reis G., ROSSI DOS SANTOS F., ROSSI P., Rydén L.E., SALA J., SARAIVA J.O.S.E., SARJANOVICH R.J., SCHIAVI L.B., SCHROE H., SCHYGIEL P.O., Störk S., VAN DE BORNE P., VAN DEN HEUVEL P.A.U.L., Vanassche T., Varigos J.D., VENSENTINI N., Verhamme P.B., VICO M., Vinereanu D., VITA N.A., VOGEL D., VRANCKX P., Widimsky P., Yan Duarte, Yusuf S., ZAIDMAN C., Zhu J., ZIMMERMANN S.L.Fuentes:scopusThe Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges
ArticleAbstract: Background: Effective treatments for COVID-19 are urgently needed, but conducting randomized trialsPalabras claves:Autores:Anand S.S., Avezum A.J., Bangdiwala S.I., Belley-Cote E.P., Beresh H., Berwanger O., Bosch J.J., Chan N., Choudhri S., Dans A.L., DIaz R., Eikelboom J.W., Farkouh M.E., Felix Camilo, Harper W.L., Hassany M., Jolly S.S., Kazmi K., Kontsevaya A., Lewis G., Loeb M., Lopes R.D., Nkeshimana M., Orlandini A., Pais P., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Sharma S.K., Tarhuni W.M., Wasserman S., Whitlock R.P., Xavier D., Xu L., Yusuf S., Yusufali A.M.Fuentes:googlescopus